Johnson & Johnson stock heads into the open after a 0.09% dip
Published on 09/21/2026 at 06:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock closed at USD 269.99 on the New York Stock Exchange on September 18, 2026, slipping 0.09 percent from the prior session. The shares traded between an intraday low of USD 267.20 and a high of USD 272.11, giving the move a relatively narrow range compared with recent weeks. Versus the reported recent level around USD 270.22 on September 19, 2026, the latest close left the stock fractionally lower on a near term basis.
September 18, 2026 in numbers
Johnson & Johnson Inc. (ISIN US4781601046) saw Friday's trading marked by modest price fluctuations as the stock oscillated between USD 267.20 and USD 272.11 before settling at USD 269.99 at 4:00 p.m. ET on September 18, 2026. Per Nasdaq data reflected in recent market overviews, this close kept the shares roughly in line with the mid September zone around USD 270, with market capitalization indications near USD 650.6 billion as of September 19, 2026. In the same period, major US equity benchmarks such as the Dow Jones Industrial Average and the Nasdaq Composite showed mixed performances into September 18, 2026, with the Dow described as ending down 0.18 percent while the Nasdaq added 0.39 percent, highlighting a rotation across sectors that left healthcare names like Johnson & Johnson moving more narrowly than high growth segments. Trading volume in Johnson & Johnson around mid September 2026 was reported in several quote summaries as remaining solid, helping to anchor the stock close to its prevailing multi month range.
Market signals for today
Today, September 21, 2026, Johnson & Johnson enters the new session without a fresh company specific release in the early hours, so attention turns to broader US market drivers that can influence large diversified healthcare groups. Recent commentary on US indices for September 18, 2026 pointed to a mixed picture, with the Dow easing and the Nasdaq gaining, a backdrop that can continue to shape sentiment for defensive pharmaceuticals and medical devices when trading resumes. Economic and policy headlines, including ongoing discussions about interest rate expectations and health care policy, remain relevant for Johnson & Johnson today, as investors weigh these factors alongside the company’s previously raised guidance and strong second quarter figures that were highlighted in recent analyses.
